GlySure Strengthens Intellectual Property Portfolio With New Patent and Core Technology Acquisition
Published: Jul 11, 2012
ABINGDON, England, July 11, 2012 /PRNewswire/ --
GlySure Limited announced today two achievements that considerably strengthen the company's intellectual property portfolio. GlySure has been awarded U.S. patent number 8,141,409 for a fully-automated calibration system to enable accurate continuous blood glucose monitoring. Concurrently, GlySure has acquired ownership of the proprietary reversible fluorescent chemistry at the core of its continuous glucose monitoring (CGM) systems.
GlySure's technology meets the clinically documented need for Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU). Whether they are diabetic or not, many critically ill patients have elevated glucose levels which increases the risk for sepsis, renal failure, the need for blood transfusions and mortality. Studies have shown that TGC in the ICU improves outcomes, reduces mortality and cuts the cost of care by enabling patients to leave the ICU faster and with fewer complications.
"The calibration patent supports our goals of providing hospitals with accurate CGM systems while reducing the labor required from already overburdened clinical staff," said GlySure CEO Chris Jones. "The issuance of this new patent along with ownership of our core chemistry gives us full control over our critical technology."
The automated calibration technology featured in GlySure's systems provides a fully-automated three-point calibration at the point of use, while maintaining sensor sterility. With GlySure's technology, the sensor is shipped within the calibrator so that the clinician can simply insert the sensor into the monitor's calibration chamber, which remains sealed during calibration. Once the cycle is complete, the clinician removes the sensor and inserts it into the patient, enabling touch-free introduction and maintaining device sterility.
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com
SOURCE GlySure Limited